<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197544</url>
  </required_header>
  <id_info>
    <org_study_id>FAVIS</org_study_id>
    <nct_id>NCT04197544</nct_id>
  </id_info>
  <brief_title>Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.</brief_title>
  <official_title>Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fernando López Zárraga</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basque Health Service</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In last few years, there is a new technology that permits the endovascular fistula creation&#xD;
      with a minimum vascular trauma and the first results show encouraging results with high&#xD;
      technical success rate, low resurgent and failure rates and good usability for hemodialysis.&#xD;
&#xD;
      The implementation of the endoFAVI realization in dialysis patients is an emergent procedure&#xD;
      that in our hospital can contribute important benefits to the patients, savings to the health&#xD;
      system, as well research and innovation in the implicate services.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of endoFAVI physiologically appropriate for the hemodialysis during the next three months to the creation.</measure>
    <time_frame>Three months next the creation</time_frame>
    <description>The absence of stenosis and thrombosis of the fistula and the racial artery flow &gt;=500 mL/min and the vein diameter &gt;= 5 mm measured by duplex ultrasonography, or successful administration of hemodialysis with 2 needles with flow &gt;= 350 mL/min.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Efficacy and Safety</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoFAVI</intervention_name>
    <description>EndoFAVI creation to patients that require vascular access for hemodialysis.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (older than 18).&#xD;
&#xD;
          -  Currently be receiving chronic dialysis, or be waiting to start the chronic dialysis&#xD;
             in the next six months.&#xD;
&#xD;
          -  Have veins with diameter &gt;= 2.0mm to the creation of the fistula, established by&#xD;
             Duplex ultrasound or venogram.&#xD;
&#xD;
          -  Have arteries with diameter &gt;= 2.0mm to the creation of the fistula, established by&#xD;
             Duplex ultrasound or venogram.&#xD;
&#xD;
          -  Cubital and radial arterial flow for the hand, confirmed with Duplex Ultrasound and/or&#xD;
             Allen test.&#xD;
&#xD;
          -  Dismissed the realization of cephalic-radius FAVI for surgical technical problems.&#xD;
&#xD;
          -  Informed Consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known central venous stenosis or narrowing of the central vein &gt; 50% according to&#xD;
             images on the same side as the creation of the planned FAV.&#xD;
&#xD;
          -  Absence of perforator that feed the target cannulation, by venogram.&#xD;
&#xD;
          -  Occlusion or stenosis &gt; 50% of the cephalic basilica vein of the target cannulation.&#xD;
&#xD;
          -  Cannulation target vein of less than 2.0 mm of diameter.&#xD;
&#xD;
          -  Significantly compromised flow (&gt;= 50% of stenosis) in the treatment arm as determined&#xD;
             by the doctor and the images.&#xD;
&#xD;
          -  Ejection fraction documented &lt;= 35% in the last 6 months.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Heart failure Class III or IV of the New York Heart Association (NYHA).&#xD;
&#xD;
          -  Hypercouagulability status demonstrated ( Antiphospholipid Syndrome, Leiden factor V,&#xD;
             Protein deficit S, ...).&#xD;
&#xD;
          -  Known hemorrhagic diathesis.&#xD;
&#xD;
          -  Documented history of drug abuse including intravenous drugs within six months of FAV&#xD;
             creation.&#xD;
&#xD;
          -  Concomitant major surgical procedure &quot;planned&quot; within three months of recruitment or&#xD;
             major previous surgery within 30 days of recruitment.&#xD;
&#xD;
          -  Known iodine contrast allergy that cannot be properly premedicated.&#xD;
&#xD;
          -  Known adverse effects for sedation and/or anesthesia that cannot be properly&#xD;
             premedicated.&#xD;
&#xD;
          -  Evidence of active infections on the day of the index procedure.&#xD;
&#xD;
          -  Life expectancy &lt; 1 year.&#xD;
&#xD;
          -  The patient is not willing to provide an written informed consent, is not&#xD;
             geographically stable and/or is not willing to cmply with the required follow-up.&#xD;
&#xD;
          -  Patient with an objective cannulation vein of more than 6 mm of deep that would&#xD;
             require a transposition procedure, defined as the elevation of an objective&#xD;
             cannulation vein nad the creation of a new fistula AV.&#xD;
&#xD;
          -  The patient is nit willing to undergo of second stage, defined as a conversion to&#xD;
             surgical FAVI, central catheter arrangement, thrombectomy/rescue fibrinolysis, stenoic&#xD;
             area angioplasty, ...&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando López Zárraga, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Basque health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando López Zárraga, Dr</last_name>
    <phone>0034 945007600</phone>
    <email>FERNANDO.LOPEZZARRAGA@osakidetza.eus</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Basque Health Service</investigator_affiliation>
    <investigator_full_name>Fernando López Zárraga</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

